go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Bristol-Myers Squibb Pharmaceutical Limited

Bristol-Myers Squibb Pharmaceutical Limited
South Country Business Park, Leopardstown, Dublin 18,
Telephone: +353 1 291 3800
Fax: +353 1 291 3899
Medical Information Direct Line: Freephone: 1 800 749 749
Medical Information e-mail: Medical.information@bms.com
Medical Information Facsimile: +44(0)20 8754 3677
Summary of Product Characteristics last updated on medicines.ie: 01/07/2011
SPC Fer-in-Sol

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 01/07/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
Date of revision of text on the SPC:   27-Jun-2011
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

The followign changes have been made to teh SPC:

Section 4.2:

Adults and the Elderly: Fer-In-Sol is not recommended for use in adults

Adults:

Prevention: 1.6 ml daily (equivalent to 200 mg ferrous sulphate)

Treatment: 1.6 ml 2-3 times daily

There is no evidence that the dosage should differ in the elderly

Section 4.3:

Contra-indications

Use in patients with known hypersensitivity to any of the ingredients. Individuals with haemochromatosis and iron overload syndromes.

 

 

 

 

Section 4.4: 

Special Warnings and Special Precautions for Use

This product should only be used for the treatment of iron deficiency anaemia diagnosed by laboratory testing, under the supervision of a medical doctor.

This product should be used with caution in patients with haemochromatosis and haemolytic anaemias. Caution is also advised in individuals with a family history of haemochromatosis or iron overload syndromes. It should be noted that these conditions may be underdiagnosed. Overdose may be fatal, particularly in children.

 

 

 

 

 Section 4.5:

 

Interactions with Other Medicinal Products and Other Forms of Interaction

The absorption of iron salts is decreased in the presence of antacids,

trientine, zinc and tetracyclines.

 

 

Iron salts diminish the absorption of tetracyclines,

ciprofloxacin, levofloxacin, norfloxacin, ofloxacin, bisphosphates, zinc salts and penicillamine. It may also reduce the absorption of entacapone and levodopa.

 

Ferrous sulphate also reduces the hypotensive effect of methyldopa.

 

 

 

Section 4.6:

Pregnancy and Lactation

Fer-in-Sol should not be taken in the first 13 weeks of pregnancy. If iron containing products are considered essential during the first 13 weeks of pregnancy they should only be taken under medical supervision.

Prophylaxis of iron deficiency during the remainder of pregnancy is justified. No contraindications are known to use in lactation.

 

 

 

 

Section 4.8:

Undesirable Effects

Side effects including nausea, vomiting, diarrhoea and/or constipation may occur.

Hypersensitivity reactions have been reported. These range from rashes, sometimes severe to anaphylaxis.

 

 



 

Updated on 22/03/2011 and displayed until 01/07/2011
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
Date of revision of text on the SPC:   14-Mar-2011
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



The following sections have been amended in the SPC:

Section 1:
TRADE .        NAME OF THE MEDICINAL PRODUCT

 FER-IN-SOL

              Fer-In-Sol 25mg/ml oral drops, solution

 

2.           QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Each 1ml of liquid contains 125mg of Ferrous Sulphate equivalent to 25mg of available iron.  Also contains Sucrose 383.1 mg/ml, Sorbitol  Solution (70%) 309.1 mg/ml and Ethanol 1.612 mg/ml.

 

For a full list of excipients, see section 6.1.

 

3.           PHARMACEUTICAL FORM

 

Oral drops, solution.

A colourless or light bluish green to yellowish brown liquid.


6.1         List of Excipients

 

Citric acid anhydrous, ethanol, lemon andoil, peppermint flavours, oil, sulphuric acid, sorbitol, sucrose, sulphuric acid, purified water.

 

6.2         Incompatibilities

 

None

Not applicable

 

6.3         Shelf Life

 

24 months

2 years

 

6.4         Special Precautions for Storage

 

              Keep the bottle tightly closed.  Do not store above 25°C.


6.6         Instructions for Use/Handling

 

None

 

 

              No special requirements’


Updated on 03/05/2006 and displayed until 22/03/2011
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
Updated on 28/05/2003 and displayed until 03/05/2006
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Ferrous Sulphate

Versions

 
01/07/2011 to Current
22/03/2011 to 01/07/2011
03/05/2006 to 22/03/2011
28/05/2003 to 03/05/2006
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo